

41548



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Kuo et al.

Serial No.: 09/910,920

Filed: 24 July 2001

For: **Phosphorylated Mannose
and Chlamydia Infectivity**

Group Art Unit: 1645

Examiner: Fields

TECH CENTER 1600/2900

JUL 08 2002

RECEIVED

8
JM
7/12/02

RESPONSE TO RESTRICTION REQUIREMENT

Box Non-Fee Amendment

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This reply is responsive to the communication mailed 6 June 2002.

REMARKS

The Examiner identified two groups of invention:

- I. Claims 1 – 8 drawn to antibody; and
- II. Claims 9 – 16 drawn to a method of treatment.

Applicants elect Group 1, Claims 1 – 8.

The Examiner also identified three distinct species. The species are mannose-6-phosphate, mannose-6-phosphate receptor and insulin-like growth factor.

Applicants elect mannose-6-phosphate.


Regarding the identification of groups, the Examiner has made an error in defining the two groups. Claims 1 and 9, the independent claims of each group, are not limited to antibody. Instead, the claims are directed to an inhibitor that prevents Chlamydia infection. An antibody is one of those types of molecules that can be used to inhibit infection and is recited in a dependent claim.

Response to Restriction Requirement
Ser. No. 09/910,920

Also, because Claims 1 and 9 are generic. When mannose-6-phosphate is found patentable, the other two species will need to be examined.

Favorable consideration and early indication of allowance are solicited earnestly.

Respectfully submitted,



Dean H. Nakamura
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036
(202) 659-9076
Dated: 3 July 2002